BioAge Labs (BIOA) Non-Current Deffered Revenue (2024 - 2025)

BioAge Labs (BIOA) reported Non-Current Deffered Revenue of $556000.0 for Q3 2025, down 70.77% sequentially from $1.9 million in Q2 2025.

BioAge Labs (BIOA) Non-Current Deffered Revenue (2024 - 2025) Analysis & Trends

BioAge Labs (BIOA) has 2 years of Non-Current Deffered Revenue data on file, last reported at $556000.0 in Q3 2025.

For the quarter ending Q3 2025, Non-Current Deffered Revenue changed N/A year-over-year to $556000.0; the trailing twelve-month figure through Sep 2025 stood at $556000.0 (changed N/A YoY), and the FY2024 full-year result was $4.7 million, changed N/A from the prior year.
Non-Current Deffered Revenue eased to $556000.0 in Q3 2025, from $1.9 million in the prior quarter.
In the past five years, Non-Current Deffered Revenue ranged from a high of $4.7 million in Q4 2024 to a low of $556000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Deffered Revenue (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn	-
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn	-
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn	-
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn	-
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn	-
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn	-
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn	-
10	BioAge Labs	930.32 Mn	930.32 Mn	-10.37 Mn	-

Download Data